• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Multi-layered control of PD-L1 expression in Epstein-Barr virus-associated gastric cancer

    2020-07-28 07:14:58ChristosMiliotisFrankSlack

    Christos N. Miliotis, Frank J. Slack

    HMS Initiative for RNA Medicine, Department of Pathology, Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

    Abstract Gastric cancer (GC) is the fifth most common cancer worldwide. In approximately 10% of GC cases, cancer cells show ubiquitous and monoclonal Epstein-Barr virus (EBV) infection. A significant feature of EBV-associated GC (EBVaGC) is high lymphocytic infiltration and high expression of immune checkpoint proteins, including programmed death-ligand 1 (PD-L1). This highlights EBVaGC as a strong candidate for immune checkpoint blockade therapy. Indeed, several recent studies have shown that EBV positivity in GC correlates with positive response to programmed cell death protein 1 (PD-1)/PD-L1 blockade therapy. Understanding the mechanisms that control PD-L1 expression in EBVaGC can indicate new predictive biomarkers for immunotherapy, as well as therapeutic targets for combination therapy. Various mechanisms have been implicated in PD-L1 expression regulation, including structural variations, post-transcriptional control, oncogenic activation of intrinsic signaling pathways, and increased sensitivity to extrinsic signals. This review provides the most recent updates on the multilayered control of PD-L1 expression in EBVaGC.

    Keywords: Epstein-Barr virus, gastric cancer, immunotherapy, programmed death-ligand 1

    INTRODUCTION

    Gastric cancer (GC) is the fifth most common and third most deadly cancer worldwide[1]. Due to the lack of early symptoms, patients are usually diagnosed with locally advanced or metastatic cancer, when conventional lines of therapy are less effective. The 5-year survival rate for GC in the United States varies by stage and ranges from 68% in patients with localized cancer to 5% in patients with distant metastases[2].

    Table 1. Immunological and molecular characteristics of GC molecular subtypes

    The majority of GCs (90%-95%) are adenocarcinomas[3]. The Cancer Genome Atlas (TCGA) recently undertook a comprehensive molecular characterization of hundreds of gastric adenocarcinomas and proposed classification of GC into four molecular subtypes: Epstein-Barr virus (EBV)-positive,microsatellite instability (MSI), chromosomal instability (CIN), and genomically stable (GS) subgroups[4].EBV-positive tumors are characterized by DNA hypermethylation, frequent phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations, and programmed cell death ligand 1(PD-L1)/programmed cell death ligand 2 (PD-L2)/Janus kinase 2 (JAK2) overexpression; MSI tumors have high mutation and DNA methylation rates; CIN tumors contain chromosomal alterations affecting mainly tyrosine kinase receptors; and fi nally, GS tumors are chromosomally stable and have a high frequency of cadherin 1 (CDH1) and Ras homolog family member A (RHOA) mutations [Table 1][4]. This review will focus on EBV-positive tumors.

    EBV is a double-stranded DNA virus that belongs to the herpesvirus family. An estimated 90% of the human population show signs of previous infection with EBV[7]. The virus is usually transmitted orally through saliva. Primary infection is most commonly asymptomatic, but it can lead to acute mononucleosis in a subset of the population, primarily adolescents and young adults[8]. Following primary infection, the virus establishes a lifelong latent infection in the host. EBV can remain latent in both lymphocytes and epithelial cells, where it expresses only a subset of its genes. Depending on which viral genes are expressed, latent EBV infection is typically classified into four latency programs, known as latency 0, I, II, and III [Table 2][7].

    In 1964, EBV was the first human virus to be associated with cancer, when it was discovered in Burkitt’s Lymphoma[9,10]. Since then, EBV has also been linked to other lymphomas, including Hodgkin lymphoma,diffuse large B-cell lymphoma (DLBCL), and Natural Killer/T-cell lymphomas (NK-T lymphomas)[11]. In addition, EBV has been associated with certain epithelial cancers, notably Nasopharyngeal Carcinoma(NPC) and GC. In both lymphoid and epithelial cancers, EBV persists in a latent state in infected cells[11].However, different EBV-associated cancers demonstrate different viral gene expression patterns [Table 2].

    Table 2. Viral genes expressed in each latency program

    In EBV-associated GC (EBVaGC), the virus expresses all latency I products, meaning EBV nuclear antigen 1 (EBNA1), Epstein-Barr encoding region small noncoding RNAs, BamHI A rightward transcripts (BARTs),and BART miRNAs, while around 50% of the cases also show Latent Membrane Protein 2A (LMP2A)expression, which is typically associated with latency II[12]. LMP1, another latency II protein, is typically not detected in EBVaGC samples[12-14]. There is strong geographical variation in the prevalence of EBVaGC but overall around 10% of gastric adenocarcinomas worldwide are classified as EBV-positive[15].

    In EBVaGC, the EBV genome is mainly maintained as a nuclear episome and cancer cells within the tumor show ubiquitous and monoclonal EBV infection[12,16]. The monoclonality of EBV infection suggests the clonal selection of virus-infected cells in early stages of cancer development. The role of EBV in gastric carcinogenesis is still under investigation, but EBV infection is thought to contribute to GC progression or maintenance, both directly through the activity of viral proteins or RNAs and indirectly through the induction of somatic alterations in the host genome and epigenome[17].

    PD-L1 EXPRESSION IN EBVAGC

    Multiple studies have shown that EBVaGC is commonly characterized by high lymphocytic infiltration in the tumor microenvironment, coupled with overexpression of immune-related genes, includingPD-L1(also known asCD274)[4,5,18]. PD-L1 is a glycoprotein, expressed by both cancer cells and stromal immune cells in the tumor, that engages the programmed cell death 1 (PD-1) receptor expressed on the surface of in filtrating cytotoxic T cells (CTLs)[19]. The interaction between PD-L1 and PD-1 leads to the inhibition of the tumor-in filtrating CTLs, preventing them from attacking and eliminating tumor cells.PD-L1is only one of multiple immune checkpoint genes that are known to be upregulated in EBV-positive compared to EBV-negative cancers.PD-L2, Lymphocyte activation gene-3 (LAG3), T cell immunoglobulin and mucin domain(Tim-3), Cluster of differentiation 80 (CD80), Cluster of differentiation 86 (CD86), and Indoleamine 2,3-dioxygenase 1 (IDO1) are also upregulated, butPD-L1has received particular interest because the PD-1/PD-L1 axis is the target of some recent breakthrough cancer therapies[20]. Monoclonal antibodies that block the interaction between PD-L1 and PD-1, thus restoring the ability of the immune system to surveil and attack the tumor, have shown promising results as therapeutic agents against multiple cancers, including non-small cell lung cancer and melanoma[19]. Recently, the Food and Drug Administration (FDA) approved pembrolizumab, a mAb targeting PD-1, as a third-line therapy for advanced gastric tumors that are positive for PD-L1 expression based on immunohistochemical (IHC) staining[21,22].

    The clinical efficacy and adverse effects of PD-1/PD-L1 therapy vary tremendously among patients. High expression of PD-L1 in the tumor has been implicated as a significant predictive biomarker for positive response to PD-1/PD-L1 therapy[23]. However, several clinical studies have demonstrated that some tumors with high PD-L1 expression do not respond to PD-1/PD-L1 therapy, while some tumors with moderate or low PD-L1 expression do show beneficial responses. This discrepancy could be attributed in part to the fact that direct determination of PD-L1 expression in the tumor, which is typically performed by IHC assays,has been proven to be difficult and inconsistent[24,25]. Understanding the molecular mechanisms that control PD-L1 expression in cancer may give rise to more accurate biomarkers for positive response to PD-1/PD-L1 therapy. In addition, regulators of PD-L1 expression could serve as targets for potential combination therapies.

    In a phase II clinical trial, Kimet al.[6]identified EBV-positivity and high mutational load as reliable and independent biomarkers for the clinical efficacy of pembrolizumab in GC patients and recommended considering pembrolizumab as an early therapeutic option for EBVaGC. MSI-high (MSI-H) tumors are characterized by high rates of somatic mutations, resulting in increased presentation of neoantigens and thus stimulation of anti-tumor immunity. As is the case in EBV-positive GCs, MSI-H tumors have high levels of tumor-infiltrating lymphocytes (TILs)[26]. The FDA has already approved the use of front-line pembrolizumab monotherapy in advanced MSI-H solid tumors of any origin, including stomach[27].

    EBVaGC appears to employ some common and some unique mechanisms for PD-L1 regulation. This review presents the most recent findings on PD-L1 regulation in EBVaGC and discusses some of the discrepancies in the literature, parallels with other EBV-associated cancers, and questions to be addressed in the future [Figure 1].

    EVOLUTIONARY PRESSURE FOR PD-L1 OVEREXPRESSION

    EBVaGC shows high levels of TILs and thus is under strong evolutionary pressure for the development of immune evasion strategies[4]. One such strategy is PD-L1 overexpression, which is evident in both cancer and stromal immune cells. It is speculated that the high immune activity in the EBVaGC microenvironment reflects the strong immunogenicity of EBV in the body. Up to 5% of the circulating CD8+T cells in EBV-infected individuals are believed to be reactive to lyticzor latent EBV antigens[28]. Indeed, several groups have detected expression of a subset of lytic genes in EBVaGC[29-31]. According to Borozanet al.[29], the lytic expression pattern detected in EBVaGC, which includes subsets of both early and late lytic proteins,does not indicate lytic, or abortive lytic, replication. However, the presentation of lytic viral antigens by infected cancer cells might be driving further immune activation. Camargoet al.[32]detected higher levels of circulating antibodies targeting both latent and lytic proteins in patients with EBV-positive compared to EBV-negative GCs, even though virtually all patients in the study were seropositive for antibodies against EBNA and the viral capsid. This further suggests that lytic proteins are expressed in EBVaGC and potentially contribute to the activation of the host immune response.

    SOMATIC STRUCTURAL VARIATIONS

    Somatic genomic alterations include short variations, such as single nucleotide substitutions and short insertions/deletions (indels), as well as long variations, also known as structural variations (SVs)[33].SVs affect large chromosomal regions (longer than 50 base-pairs) and include amplifications, deletions,inversions, and translocations[33]. Somatic changes occur continuously in the life of an individual and are usually repaired, but their accumulation over time can contribute to carcinogenesis[33]. EBVaGC only appears in a small percentage of EBV-infected individuals and typically long after primary EBV infection suggesting that somatic genomic changes are likely required for cancer development[34].

    Gene amplification

    Recent high-throughput sequencing studies have revealed different genomic alterations that lead to PD-L1 overexpression in EBVaGC. TCGA performed a somatic copy-number aberrations analysis in gastric adenocarcinoma samples and identified a frequent (15% of EBVaGC cases) somatic focal amplification at the chromosomal region 9p24.1, which includes the genesPD-L1,PD-L2, andJAK2[4]. This amplification was significantly more common in EBV-positive than EBV-negative tumors. Importantly, they showed that the 9p24.1 amplification correlated positively withPD-L1mRNA levels in the tumor[4]. Saitoet al.[35]detected 9p24.1 amplification events at a similar rate in a different EBVaGC cohort and demonstrated a direct association betweenPD-L1copy number and protein expression. Using fluorescence in-situ hybridization and IHC staining, they showed thatPD-L1genomic amplifications were specifically detected in cancer cells that showed high PD-L1 protein expression. Similar amplification patterns have been detected in other cancers, including hepatocellular carcinomas (HCC) and DLBCL[23,36].

    Figure 1. The mechanisms of PD-L1 regulation in EBVaGC discussed in this review. EBV: Epstein-Barr virus; EBVaGC: EBV-associated gastric cancer; PD-L1: programmed cell death ligand 1; IFNγ: interferon gamma; TNFα: tumor necrosis factor alpha; EBER: Epstein-Barr encoding region; JAK: Janus kinase; STAT: signal transducers and activators of transcription; IRF: interferon regulatory factor 1;EBNA1: EBV nuclear antigen 1; BART: BamHI A rightward transcripts; PIAS: protein inhibitor of activated STAT 3; IκBα: nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha; NFκB: nuclear factor kappa-light-chain-enhancer of activated B cells; LMP2A: latent membrane protein 2A; PTEN: phosphatase and tensin homolog; PIK3CA: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha; PI3K: phosphoinositide 3-kinase; AKT: protein kinase B; ARID1A: AT-rich interaction domain 1A; mTOR:mammalian target of rapamycin; 3′-UTR: 3′ untranslated region; SV: structural variation; SNV: single nucleotide variation; BHRF1: BamHI fragment H rightward open reading frame 1. Created with BioRender.com

    Integration of EBV to the host genome

    In EBVaGC, the EBV genome is mostly maintained in the nucleus as a circular episome[16]. Some studies have also reported viral integration events, even though they are considered rare[4,37,38]. TCGA identified the presence of RNA sequencing (RNAseq) reads corresponding to a fusion between the hostPLGRKTgene and the EBV geneBHLF1in one EBVaGC sample (FP-7998-01)[4]. This is notable given that thePLGRKTlies within the 9p24.1 chromosomal region and is adjacent to thePD-L1locus. It was later shown in the same sample, that the amplified region containing the integrated EBV genome (Copy Number = 4) has a breakpoint in thePD-L13’ untranslated region (3’-UTR)[37]. Xuet al.[38]performed a genome-wide EBV integration analysis in multiple malignancies and identified that EBV integrates primarily in unstable chromosomal regions of the host genome. They identified EBV integration events in 25% (10/39) of the GC samples analyzed, with some of the integration breakpoints mapping close to known tumor suppressor genes[38]. None of their samples had integrated virus close toPD-L1,but studies with bigger EBVaGC sample sizes are necessary to identify the frequency and significance of viral integration in or close to thePD-L1locus. Viral integration in the host genome has been associated with increased PD-L1 expression in other virus-associated cancers. Caoet al.[20]identified integrated HPV genomes in thePD-L1orPD-L2loci in three cases from the TCGA Head and Neck Squamous Cell Carcinoma cohort and showed that these integration events correlated with elevated PD-L1 and PD-L2 expression.

    3’-UTR structural variations

    SVs in thePD-L13’-UTR have also been associated with increased PD-L1 expression in EBVaGC[34,37].Kataokaet al.[37]analyzed RNAseq data from all TCGA cancer types and searched for 3’-UTR disruptions inPD-L1. The authors identifiedPD-L13’-UTR truncations in 31/10,210 cancer cases and showed that they correlated with high PD-L1 expression. The highest frequency of 3’-UTR truncations was found in DLBCL(4/48) and GC (9/415), with a third of the GC samples (3/9) being EBV-positive. Therefore, around 10% of EBVaGC samples in TCGA were found to havePD-L13’-UTR SVs[34,37]. In a follow-up study, Kataokaet al.[34]analyzed samples from multiple EBV-associated lymphomas and found thatPD-L13’-UTR SVs were significantly more common in EBV-positive compared to EBV-negative lymphomas. They report thatPD-L13’-UTR genomic truncations in cell lines and mouse models promote PD-L1 overexpression and immune evasion, consistent with the patient data[37].

    POST-TRANSCRIPTIONAL REGULATION

    The 3’-UTR contains sequences or structural regions, called regulatory elements, that are important for the post-transcriptional regulation of a gene. These regulatory elements control binding to miRNAs and RNA-binding proteins (RBP), which in fluencem RNA stability, translation rate, and localization[39]. miRNAs are short non-coding RNAs that silence gene expression by binding to complementary sequences in the 3’-UTR of target mRNAs. miRNA-mRNA binding usually triggers mRNA degradation or blocks translation. The fact that 3’-UTR shortening has such a profound effect on PD-L1 expression in multiple cancers indicates that PD-L1 is under tight post-transcriptional control[37].

    3’-UTR short variations

    Mutations in the 3’-UTR have the capacity to remove existing or create new binding sites for miRNAs and RBPs. Some germline and somatic mutations in the 3’-UTR ofPD-L1have been shown to correlate with PD-L1 expression in gastric and other cancers[40-44]. Wuet al.[43]analyzed 728 GC samples and found that the AA and AG genotypes in rs2297136, a germline single nucleotide polymorphism (SNP) located in the 3’-UTR ofPD-L1, were associated with lower PD-L1 protein levels. They reported that the miRNAs miR-324-5p and miR-362 are predicted to bind to that region of thePD-L13’-UTR, but no validation experiments were pursued. Wanget al.[44]polymerase chain reaction (PCR)-amplified and sequenced the 3’-UTR ofPD-L1in hundreds of GC and matched normal samples and identified a frequent guanineto-cytosine somatic mutation that correlated with increased PD-L1 protein expression. It was shown that this mutation maps to a seed-binding region for miR-570 and it was proven experimentally that it increases PD-L1 expression by disrupting miR-570 binding[44]. To date, most studies looking atPD-L13’-UTR mutations have been low-throughput, with small sample sizes or targeted on speci fi c SNP locations.There has not been a comprehensive study looking at the frequency and effect of all possible somatic and germline variants in thePD-L13’-UTR in EBVaGC or other EBV-associated cancers. The fact that SVs in thePD-L13’-UTR appear to occur more frequently in EBV-positive than EBV-negative cancers raises the question of whether short variants in the 3’-UTR could be an alternative or parallel mechanism for PDL1 overexpression. Large-scale variant calling studies in gastric and other cancers, including the TCGA somatic mutation data, have mostly relied on whole exome sequencing data and exclude 3’-UTR sequences.This has created a gap in our understanding of 3’-UTR variations in cancer in general.

    Host miRNAs and RBPs

    Multiple miRNAs have been implicated in the control of PD-L1 expression in GC[45]. Some miRNAs,such as miR-152 and miR-200, target the 3’-UTR of PD-L1 directly. Other miRNAs, such as miR-19a and miR-19b, affect PD-L1 levels indirectly, by targeting signaling pathways or transcription factors that regulate PD-L1 expression[45-48].

    EBVaGC has been reported to exhibit a distinct host miRNA expression profile from other GC subtypes[4,49,50]. Differentially expressed miRNAs include ones that have been independently shown to target PD-L1, with the most notable example being miR-200[48]. miR-200 is a family of miRNAs found in two distinct genomic clusters and consists of miR-200a, miR-200b, miR-429, miR-200c, and miR-141[51].miR-200a, miR-200b, and miR-429 form a cluster on chromosome 1, while miR-200c and miR-141 form a cluster on chromosome 12. miR-200b, miR-200c and miR-429 share the same seed sequence, while miR-200a and miR-141 have a seed sequence that differs from the others by one nucleotide. ThePD-L13’-UTR contains one binding site for each seed-sharing functional cluster of miR-200 miRNAs and all miR-200a, b, and c have been shown to directly silence PD-L1 expression[48].

    The miR-200 family has been shown to be downregulated in EBV-positive compared to EBV-negative GC samples, as well as in EBV-negative GC cells following infection with recombinant EBV (rEBV)in vitro[52,53].Whether or how EBV latent proteins downregulate miR-200 remains unclear. Shinozakiet al.[53]reported that overexpression of any ofEBNA1,LMP2A, orBARF0(aBARTtranscript) in EBV-negative GC cells (MKN74 cell line) leads to miR-200a/b transcriptional repression, while overexpression of EBERs downregulates the mature miRNAs post-transcriptionally. The authors concluded that EBV latent proteins and RNAs act synergistically to downregulate miR-200. This is in contrast with a study by Marquitzet al.[52]on a different EBV-negative GC cell line, AGS. They reported that rEBV-infected AGS (AGS-EBV)cells showed consistent downregulation in some tumor suppressor miRNAs, including miR-200, when compared to the parental uninfected cells. However,EBNA1orLMP1overexpression in AGS did not affect the expression levels of miR-200 and most of the other EBV-downregulated miRNAs[52]. They speculate that EBV-mediated cellular miRNA downregulation might not be mediated by the latent viral proteins,but by viral miRNAs, through their effect on host transcription factors, or by EBERs[52]. Another possible mechanism of host miRNA downregulation in EBV-infected cells is methylation of their promoter sequences. EBV infection in GC cells has been shown to promote extensive DNA methylation, partly through the activity of the latent protein LMP2A, which induces DNA methyltransferases (DNMTs)[54,55].Indeed, the miR-200c promoter contains CpG islands that have been shown to be methylated by DNMT3a in GC[56].

    Research from our group described an EBV gene/host miRNA/PD-L1 regulation axis in B cell lymphomas,where the EBV protein EBNA2 induces PD-L1 expression by transcriptionally repressing miR-34a, a miRNA that downregulates PD-L1[57]. EBNA2 is a latency III-associated protein and thus is not expressed in GC. However, miR-34a has been shown to be downregulated in GC overall and to be transcriptionally repressed by EBNA1 in EBVaGC[58,59].

    ThePD-L13’-UTR contains multiple adenosine-uridine (AU)-rich elements (AREs) that are known to serve as binding sites for different RBPs[60]. In GC, the RBP tristetraprolin (TTP) has been shown to bind to AREs in thePD-L13’-UTR and to promote mRNA destabilization, leading to reduced PD-L1 expression[62].In addition, in NPC, the EBV latent protein LMP1 reduces TTP expression through extracellular-signalregulated kinase 1/2 (ERK1/2) activation[63]. Nonetheless, there has not been an association between EBV infection and TTP expression in GC.

    Viral miRNAs

    EBV expresses 25 precursor miRNAs (pre-miRNAs) and 44 mature miRNAs. Three pre-miRNAs are derived from the BamHI fragment H rightward open reading frame 1 (BHRF1) region of the viral genome,while the rest are derived from the BART region[64]. BART miRNAs are thought to play an important role in EBVaGC and are highly abundant, accounting for up to 15-20% of the total miRNA pool in some EBVaGC cell lines[65]. Some studies have demonstrated that xenografts of EBV-infected GC cell lines, including AGSEBV and SNU719 cells, in immunocompromised mice show up to 10- or 100-fold overexpression of BART miRNAs compared to their parental cell lines[66,67]. This suggests that BART miRNAs might be particularly important for cancer progressionin vivo. BART miRNAs are known to play a range of roles in GC,targeting host cell apoptosis, cell cycle, and metastasis[68,69]. Their role in immune evasion is less well studied in GC, although multiple immune-related functions have been attributed to BART miRNAs in other EBV-associated cancers[64].

    In contrast to BART miRNAs, which are expressed in all EBV latent stages, BHRF1 miRNAs are thought to be expressed only in latency III and lytic replication. BHRF1 miRNAs are commonly reported as barely detectable in GC tissues and cell lines[4,54,62]. However, Treeceet al.[49]analyzed miRNA expression in FFPE tissues from 78 cases of gastric adenocarcinoma, including 20 EBVaGCs, and reported that BHRF1-2-5p was signi fi cantly overexpressed in EBV-infectedvs.EBV-negative cancers, although to a lower extent than BART miRNAs. Marquitzet al.[52]also detected low expression of BHRF1 miRNAs in sequencing from EBV-infected GC cells (AGS-EBV). Both groups attributed the detection of BHRF1 miRNAs to possible low levels of viral replication. Given that several studies have reported the expression of a subset of lytic transcripts in EBVaGC, even in the absence of lytic replication, the level and importance of BHRF1 miRNA expression remain to be determined. In anin vitromodel of EBV-driven B-cell differentiation, BHRF1-2-5p was found to downregulate PD-L1[70]. The same study identified potential binding sites for some BART miRNAs in thePD-L13’-UTR, including BART19-3p, but overexpression of the miRNA did not appear to influence PD-L1 expression. Four BART miRNAs, BART2-5p, BART7-3p, BART14-3p, miR-BART22 were found to interact withPD-L1mRNA in a high-throughput photoactivatable ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-CLIP) study in lymphoblastoid cell lines, but no validation experiments have been performed[71,72]. A recent study reported that miR-BART5-5p, which shares seed homology with the host miRNAs miR-18a-5p and miR-18b-5p,leads to signal transducers and activators of transcription 3 (STAT3)-dependent transcriptional PDL1 upregulation by targeting the STAT3 inhibitor Protein Inhibitor Of Activated STAT 3 (PIAS3)[73].

    INTRINSIC SIGNALING

    PD-L1 expression can be dysregulated by oncogenic activation of signaling pathways like the JAK/STAT,phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR),Mitogen-activated protein kinase/ERK kinase (MEK)/ERK, and Jun/Activator protein 1 (AP-1) pathways.These pathways act independently or synergistically to control PD-L1 expression, at the transcriptional,post-transcriptional, and post-translational stage[74-76]. Their importance in PD-L1 regulation tends to vary among different cancer types. The constitutive activation of an intrinsic signaling pathway in cancer is usually the result of mutations or SVs in genes of key components or regulators of the pathway. In the case of virus-associated cancers, viral proteins can also induce constitutive signaling in infected cells.

    Signaling activation by host gene mutations

    A frequently mutated gene in EBVaGC cancer isPIK3CA, which encodes a catalytic component of the PI3K kinase[4,77]. The most common variants inPIK3CAare associated with increased PI3K signaling activity[77]. The PI3K pathway is thought to regulate PD-L1 expression in a tissue-speci fi c manner. Loss of Phosphatase and tensin homolog (PTEN) leads to activation of the PI3K pathway and induction of PDL1 expression in gliomas and colorectal cancer[78,79]. In gliomas, Parsaet al.[79]showed that the PI3K/Akt/mTOR pathway increasesPD-L1mRNA translation through polysomal recruitment. In the case of GC,there is con fl icting evidence for the importance of the PI3K pathway in PD-L1 regulation. Supporting the importance of PI3K signaling in promoting PD-L1 expression, Kimet al.[80]showed that the PI3K inhibitor

    LY294002 reduced PD-L1 expression in three GC cell lines. In addition, Menyhártet al.[81]performed hierarchical clustering to determine the mutations that could best stratify TCGA GC patients based on PD-L1 expression. They showed that the mutation status ofPIK3CAserved as the best root node for the stratification, while mutations in other immune-related genes likeMEF2C,SLC11A1, andKIF15could help further refine it, suggesting potential interactions between these genes for the control of PD-L1 expression[81]. However, Mimuraet al.[82]performed experiments with a panel of GC cell lines and determined that the PI3K inhibitor wortmannin did not affect PD-L1 expression. Besides, Seoet al.[77]analyzed 112 EBV-positive GC samples and reported thatPIK3CAmutations did not show any correlation with PD-L1 expression or TIL abundance. Therefore, the importance ofPIK3CAmutations and PI3K signaling in the control of PD-L1 expression in GC and EBVaGC is still unclear, and may be dependent on interactions with other mutations and signaling pathways.

    Another gene that is commonly mutated in EBVaGC is AT-Rich Interaction Domain 1A (ARID1A),which encodes an important component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex[4]. Mutations inARID1Aare usually loss-of-function mutations. Kimet al.[80]analyzed 273 GC samples and showed that ARID1A protein loss correlated with PD-L1 positivity (as defined by IHC staining), independently of EBV or MSI status. They also showed thatARID1Aknockdownin vitrodirectly leads to PD-L1 overexpression, through the activation of the PI3K/Akt pathway. To account for the variability in PD-L1 expression amongARID1A-mutated tumors, the authors looked for additional mutations that could be acting synergistically withARID1Amutations. They foundKRASmutations in the threeARID1A-mutated MSI-H tumors with the highest PD-L1 expression, while two other samples that harboredKRASbut notARID1Amutations did not show elevated PD-L1 levels. These data further suggest that PD-L1 expression is controlled by multiple oncogenic signaling pathways acting in coordination.

    Signaling activation by viral latent proteins

    The EBV latent membrane proteins (LMPs) are potent oncoproteins and are known to activate oncogenic signaling cascades in EBV-associated malignancies. In epithelial cancers, LMP2A has been found to regulate the nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), PI3K/Akt, MEK/ERK,and transforming growth factor beta (TGFβ) pathways[83-86]. In GC speci fi cally, LMP2A has been reported to lead to constitutive NFκB activation by inhibiting the expression of the nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα), which negatively regulates NFκB activity[83,84].The mechanism of IκBα downregulation appears to be unrelated to promoter methylation and remains to be determined. Independent studies have shown that NFκB promotes PD-L1 transcription in GC[87-89], but no direct association has been made between LMP2A, NFκB, and PD-L1. As mentioned above, LMP2A is also thought to be important for promoting the DNA hypermethylated state observed in EBVaGC.Hinoet al.[90]showed that LMP2A induces phosphorylation and activation of STAT3, which in turn leads to overexpression of DNMT1, thus changing the DNA methylation landscape of the cell. They showed that one of the targets of DNMT1 isPTEN, which encodes a negative regulator of the PI3K pathway. The hypermethylation of thePTENpromoter reduces PTEN expression and leads to overactivation of the PI3K pathway[90]. Interestingly, PTEN is also known to be directly targeted by miR-BART1 and BART7-3p in NPC[91,92]. Moonet al.[93]reported that the small interfering RNA (siRNA)-mediated knockdown of LMP2A did not affect PD-L1 expression in SNU719, an EBVaGC cell line. However, more studies with additional methods of manipulating LMP2A expression and activity are required to elucidate its role in PD-L1 regulation.

    INTERFERON GAMMA-INDUCIBLE PD-L1 EXPRESSION

    Multiple studies have reported that GC patients with higher levels of CD8+TILs also have higher PD-L1 expression[94-96]. This suggests that PD-L1 overexpression in EBVaGC is at least partly a result of the evolutionary pressure from the adaptive immune response acting against the cancer. When CD8+T cells are activated, such as through the recognition of neoantigens or viral antigens presented by cancer cells, they produce in fl ammatory cytokines like tumor necrosis factor alpha (TNFα) and interferon gamma (IFNγ)[97,98].IFNγ has been shown to induce PD-L1 expression in various cancers[99]. In GC, PD-L1 induction by IFNγ appears to occur mainly through the JAK/STAT/Interferon regulatory factor 1 (IRF1) signaling axis[82,100-102].The extent to which different cancer cells are responsive to IFNγ and the downstream effects of IFNγ exposure vary among cancer types and molecular subgroups within a cancer type.

    In TCGA and other GC cohorts, when EBVaGC samples are compared to EBV-negative ones, they demonstrate elevated IFNγ signatures, indicated by higher expression of IFNγ, JAK/STAT signaling components, and several IFNγ-induced genes[4,103]. In addition,in vitrostudies have shown that EBVaGC cell lines induce PD-L1 expression in response to IFNγ to a much higher extent than EBV-negative GC cell lines[93,104]. PD-L1 induction in response to IFNγ has also been shown to be significantly elevated in other EBV-associated epithelial malignancies, such as NPC[105]. In NPC, the viral protein LMP1 acts synergistically with IFNγ to induce PD-L1 expression through the activation of the JAK3/STAT3,NFκB, and AP-1 signaling pathways. In GC, EBNA1 has been shown to promote IFNγ-induced PD-L1 overexpression. Moonet al.[93]showed thatEBNA1knockdown in SNU719, an EBVaGC cell line, resulted in the transcriptional downregulation of JAK2.EBNA1knockdown also resulted in a small but signi fi cant reduction in constitutive and IFNγ-induced PD-L1 levels. However, ectopic EBNA1 expression in the EBV-negative GC cell line AGS did not affect constitutive or IFNγ-induced PD-L1 expression. In contrast,Suet al.[106]reported that AGS-EBV cells are more sensitive to IFNγ/TNFα treatment, showing higher downstream PD-L1 upregulation, than the uninfected parental cell line. This suggests that other viral factors, in addition to EBNA1, might be necessary for increasing IFNγ-induced PD-L1 expression in EBV-infected GC cells. Further studies are required to determine how EBNA1 and other viral or host factors promote increased IFNγ sensitivity and PD-L1 expression in EBVaGC.

    Nakayamaet al.[107]analyzed 43 EBVaGC samples and showed that the number of EBV genomes per cancer cell (EBV copy number) correlates positively with PD-L1 expression. Similarly, Stronget al.[31]performed cellular gene expression analysis on 12 EBV-positive and 20 EBV-negative TCGA GC samples and showed that, following hierarchical clustering, the 4 EBV-positive samples that had a much higher EBV coverage depth (in RNAseq data) than the rest of the EBV-positive samples formed a well-defined gene expression cluster. When they compared expression between “high” and “l(fā)ow” EBV GC samples, a large proportion of the genes that were upregulated in the “high” EBVaGC group were immune-related, including IFNγ,STAT1, IRF1, and multiple IFNγ-induced genes[31]. As the authors state, EBERs, which have been shown to induce IFNγ and TNFα production in peripheral blood mononuclear cellsin vitro, could be contributing to the elevated IFNγ signature found in “high” compared to “l(fā)ow” EBV GC samples[108].

    CONCLUSION

    Even though GC is declining in the United States, it still has one of the lowest 5-year survival rates of any cancer type[2]. This highlights the need for new therapeutic strategies, especially for metastatic cases that have the poorest prognosis and account for most of the new diagnoses every year. The molecular heterogeneity of GC correlates with the response rate to different therapies, indicating that different approaches should be considered for different molecular subgroups. The FDA recently approved pembrolizumab as second-line therapy for patients with advanced MSI-H tumors of any type, including GC[109]. In the last few years, several molecular and clinical studies present EBVaGC as another subgroup of GC that could benefit from early-line treatment with immune checkpoint inhibitors[6,107].

    In EBVaGC, high immune activation in the tumor microenvironment likely acts as a driving force for the selection of immune escape mechanisms such as PD-L1 overexpression. Different mechanisms act independently or synergistically to induce PD-L1 expression. These include somatic genomic modifications,oncogenic activation of intrinsic signaling pathways, increased sensitivity to PD-L1 inducing signals from the tumor microenvironment, and post-transcriptional control mechanisms. Overall, the regulation of PD-L1 expression in EBVaGC is poorly understood and further studies are necessary to explain how EBV and host factors contribute to it. Insight into the important genetic and epigenetic factors that control PD-L1 expression in EBVaGC and other cancers could reveal new biomarkers for positive response to immunotherapy, as well as novel therapeutic targets.

    DECLARATIONS

    Acknowledgments

    We especially appreciate Dr. Maria Mavrikaki, Allison Baker, Tanvi Saxena, and Jason Nomburg for their comments on this manuscript.

    Authors’ contributions

    Wrote the manuscript: Miliotis CN, Slack FJ

    Availability of data and materials

    Not applicable.

    Financial support and sponsorship

    Slack FJ acknowledges the NCI Outstanding Investigator Award (R35CA232105) and the support of the Ludwig Institute at Harvard and the V Foundation.

    Conflicts of interest

    Slack FJ discloses financial interests and SAB roles with Mira DX and MiRNA Therapeutics. The other author declares no competing financial interest.

    Ethical approval and consent to participate

    Not applicable.

    Consent for publication

    Not applicable.

    Copyright

    ? The Author(s) 2020.

    中文字幕人妻熟人妻熟丝袜美| 久久久久久久午夜电影| 午夜福利在线观看免费完整高清在 | 久久精品久久久久久噜噜老黄 | 国产精品电影一区二区三区| 精品日产1卡2卡| 精品一区二区三区视频在线| 丰满乱子伦码专区| 亚洲精品成人久久久久久| 看十八女毛片水多多多| 国产av麻豆久久久久久久| 色av中文字幕| av女优亚洲男人天堂| 听说在线观看完整版免费高清| 男女做爰动态图高潮gif福利片| 精品一区二区三区人妻视频| 亚洲在线自拍视频| 欧美成人a在线观看| 一级a爱片免费观看的视频| 久久久久久九九精品二区国产| 国产老妇女一区| 搞女人的毛片| 免费在线观看日本一区| 亚洲av电影不卡..在线观看| 午夜激情欧美在线| 最后的刺客免费高清国语| 美女xxoo啪啪120秒动态图| 99热只有精品国产| 色在线成人网| 国产精品久久久久久久电影| 99热精品在线国产| 午夜福利成人在线免费观看| 熟女人妻精品中文字幕| 国产精品久久视频播放| 岛国在线免费视频观看| 国产亚洲91精品色在线| 美女大奶头视频| 亚洲一区二区三区色噜噜| 免费看光身美女| 亚洲中文日韩欧美视频| 国产精品一区二区免费欧美| 精品午夜福利视频在线观看一区| 最后的刺客免费高清国语| 97人妻精品一区二区三区麻豆| 国产高潮美女av| 免费在线观看影片大全网站| 白带黄色成豆腐渣| 日日摸夜夜添夜夜添av毛片 | 国产一区二区三区视频了| 亚洲,欧美,日韩| 午夜久久久久精精品| 韩国av在线不卡| 毛片女人毛片| 日韩av在线大香蕉| 日本a在线网址| 噜噜噜噜噜久久久久久91| 国产av不卡久久| av国产免费在线观看| 男女啪啪激烈高潮av片| 在线观看免费视频日本深夜| 国产精品一区二区三区四区免费观看 | 99热网站在线观看| 亚洲成人精品中文字幕电影| 亚洲美女黄片视频| 97碰自拍视频| 日韩精品青青久久久久久| 国内精品美女久久久久久| 熟妇人妻久久中文字幕3abv| 国产伦精品一区二区三区四那| 亚洲第一电影网av| 老司机午夜福利在线观看视频| 乱系列少妇在线播放| 亚洲七黄色美女视频| 国产精品久久久久久精品电影| 午夜福利18| av在线蜜桃| av.在线天堂| 亚洲欧美日韩东京热| 国产亚洲精品av在线| 中文字幕久久专区| 真实男女啪啪啪动态图| 校园春色视频在线观看| 精品日产1卡2卡| 蜜桃亚洲精品一区二区三区| 成年免费大片在线观看| 亚洲国产色片| 免费观看的影片在线观看| 亚洲aⅴ乱码一区二区在线播放| 最近视频中文字幕2019在线8| 99热只有精品国产| 日韩欧美三级三区| 亚洲成人中文字幕在线播放| 91av网一区二区| 少妇人妻一区二区三区视频| eeuss影院久久| 一级黄色大片毛片| 真人做人爱边吃奶动态| 日韩欧美在线二视频| 少妇人妻精品综合一区二区 | 干丝袜人妻中文字幕| 午夜精品在线福利| 亚洲性夜色夜夜综合| 亚洲一级一片aⅴ在线观看| 欧美不卡视频在线免费观看| 久久这里只有精品中国| 波多野结衣高清作品| 男女做爰动态图高潮gif福利片| 欧美另类亚洲清纯唯美| av视频在线观看入口| 女生性感内裤真人,穿戴方法视频| 日本色播在线视频| 一区二区三区高清视频在线| 亚洲精品一卡2卡三卡4卡5卡| 国产精品亚洲美女久久久| 亚洲成av人片在线播放无| 一本精品99久久精品77| 日韩欧美在线二视频| 欧美中文日本在线观看视频| 99在线视频只有这里精品首页| 禁无遮挡网站| 美女cb高潮喷水在线观看| 高清毛片免费观看视频网站| 一区二区三区免费毛片| 91在线精品国自产拍蜜月| 黄色视频,在线免费观看| 久久久久久久午夜电影| 狂野欧美激情性xxxx在线观看| 琪琪午夜伦伦电影理论片6080| or卡值多少钱| 我的老师免费观看完整版| 成年女人毛片免费观看观看9| 在线免费十八禁| 我要搜黄色片| 搡老妇女老女人老熟妇| 俄罗斯特黄特色一大片| 亚洲熟妇熟女久久| 国产成人福利小说| 精品久久久久久久久av| 男女边吃奶边做爰视频| 亚洲国产欧美人成| 麻豆国产97在线/欧美| 床上黄色一级片| 国产成人福利小说| 欧美日韩中文字幕国产精品一区二区三区| 日韩欧美三级三区| 免费电影在线观看免费观看| 精品乱码久久久久久99久播| 国产av不卡久久| 国产高清视频在线观看网站| 国产精品一及| 变态另类丝袜制服| a级毛片免费高清观看在线播放| 国产精品三级大全| 99热只有精品国产| 琪琪午夜伦伦电影理论片6080| 九九热线精品视视频播放| 深爱激情五月婷婷| 日韩欧美免费精品| 最近中文字幕高清免费大全6 | 久久午夜亚洲精品久久| 日韩亚洲欧美综合| 在线免费十八禁| x7x7x7水蜜桃| 性欧美人与动物交配| 乱码一卡2卡4卡精品| 免费观看精品视频网站| 午夜视频国产福利| 伦精品一区二区三区| 日韩精品中文字幕看吧| 国产视频一区二区在线看| 国产高潮美女av| 日本与韩国留学比较| 日韩欧美精品v在线| 色噜噜av男人的天堂激情| 婷婷六月久久综合丁香| 搡女人真爽免费视频火全软件 | 色综合婷婷激情| 亚洲中文日韩欧美视频| 尾随美女入室| 看十八女毛片水多多多| 亚洲经典国产精华液单| 亚洲 国产 在线| 久久久久久久久大av| 国产蜜桃级精品一区二区三区| 国产精品久久久久久精品电影| 男女做爰动态图高潮gif福利片| 日本精品一区二区三区蜜桃| АⅤ资源中文在线天堂| 午夜福利欧美成人| 欧美+亚洲+日韩+国产| 中文字幕久久专区| 亚洲av中文字字幕乱码综合| 国产精品不卡视频一区二区| 免费av观看视频| 黄色一级大片看看| 免费av不卡在线播放| 国产极品精品免费视频能看的| 国内精品美女久久久久久| 成人av一区二区三区在线看| 嫩草影视91久久| eeuss影院久久| 88av欧美| 哪里可以看免费的av片| 淫秽高清视频在线观看| 校园人妻丝袜中文字幕| 久久久久国内视频| 久久久国产成人免费| 国产麻豆成人av免费视频| 两人在一起打扑克的视频| av黄色大香蕉| 国产伦精品一区二区三区四那| 国产免费男女视频| 亚洲人成网站在线播放欧美日韩| 午夜影院日韩av| 黄片wwwwww| 国产主播在线观看一区二区| 亚洲av成人av| 乱人视频在线观看| 亚洲国产精品成人综合色| 国产中年淑女户外野战色| 女的被弄到高潮叫床怎么办 | 国产 一区精品| 91麻豆精品激情在线观看国产| 天堂动漫精品| 亚洲性夜色夜夜综合| 一区二区三区免费毛片| 久9热在线精品视频| 丰满乱子伦码专区| 国产高清视频在线观看网站| 床上黄色一级片| 欧美在线一区亚洲| 久久九九热精品免费| 欧美色视频一区免费| 欧美色欧美亚洲另类二区| 国内久久婷婷六月综合欲色啪| av在线老鸭窝| 欧美日本视频| 伦理电影大哥的女人| 国产熟女欧美一区二区| av中文乱码字幕在线| 香蕉av资源在线| 欧美性猛交╳xxx乱大交人| 日本一二三区视频观看| 18禁黄网站禁片午夜丰满| 欧美3d第一页| 欧美另类亚洲清纯唯美| 天堂网av新在线| 内射极品少妇av片p| 午夜福利在线观看免费完整高清在 | 一级黄色大片毛片| av福利片在线观看| 97碰自拍视频| 亚洲自拍偷在线| 免费电影在线观看免费观看| 色综合站精品国产| 啪啪无遮挡十八禁网站| x7x7x7水蜜桃| 精品久久久久久久久久久久久| 99热精品在线国产| 少妇高潮的动态图| 1000部很黄的大片| 午夜福利欧美成人| 久久精品影院6| 女人十人毛片免费观看3o分钟| 简卡轻食公司| 亚洲图色成人| 淫妇啪啪啪对白视频| 国产精品99久久久久久久久| 亚洲av五月六月丁香网| 夜夜看夜夜爽夜夜摸| 午夜福利高清视频| 亚洲美女视频黄频| or卡值多少钱| 给我免费播放毛片高清在线观看| 一级黄片播放器| 国产又黄又爽又无遮挡在线| 在线观看舔阴道视频| 亚洲一区二区三区色噜噜| 久久久久久九九精品二区国产| 国产 一区精品| 久久精品综合一区二区三区| 国模一区二区三区四区视频| 国产真实乱freesex| 国内久久婷婷六月综合欲色啪| 人人妻人人看人人澡| 午夜福利在线观看免费完整高清在 | 国产精品久久久久久精品电影| 国产av不卡久久| 国产一区二区三区在线臀色熟女| 国产亚洲精品久久久com| 老司机福利观看| 亚洲成av人片在线播放无| 婷婷亚洲欧美| 91午夜精品亚洲一区二区三区 | 亚洲人成伊人成综合网2020| 精品人妻一区二区三区麻豆 | 男人和女人高潮做爰伦理| 欧美丝袜亚洲另类 | 2021天堂中文幕一二区在线观| 国产不卡一卡二| 有码 亚洲区| 在线观看午夜福利视频| 韩国av在线不卡| 成人一区二区视频在线观看| 少妇高潮的动态图| 日韩欧美国产一区二区入口| 精品久久久久久久久亚洲 | 99久国产av精品| 亚洲三级黄色毛片| 白带黄色成豆腐渣| 国产精品无大码| 欧美日韩中文字幕国产精品一区二区三区| 日韩欧美精品免费久久| 日韩欧美在线二视频| 两性午夜刺激爽爽歪歪视频在线观看| 午夜福利高清视频| 日韩欧美三级三区| 一区二区三区免费毛片| 国产69精品久久久久777片| 日日摸夜夜添夜夜添小说| 精品一区二区三区人妻视频| 日韩欧美一区二区三区在线观看| 我要看日韩黄色一级片| 亚洲av免费高清在线观看| 亚洲不卡免费看| 国内精品一区二区在线观看| 成人三级黄色视频| 美女xxoo啪啪120秒动态图| 精品人妻熟女av久视频| 精品一区二区三区av网在线观看| 亚洲国产高清在线一区二区三| 99久久精品热视频| 亚洲精华国产精华精| 亚洲av电影不卡..在线观看| 午夜福利在线观看免费完整高清在 | 一级a爱片免费观看的视频| 国产国拍精品亚洲av在线观看| 亚洲国产精品成人综合色| 成年免费大片在线观看| 午夜日韩欧美国产| 午夜福利高清视频| 99在线人妻在线中文字幕| 日韩 亚洲 欧美在线| 国产欧美日韩精品一区二区| 午夜福利在线观看免费完整高清在 | 婷婷精品国产亚洲av在线| 国产精品野战在线观看| 麻豆av噜噜一区二区三区| 丰满人妻一区二区三区视频av| 免费高清视频大片| 国产精品三级大全| 亚洲欧美日韩卡通动漫| 国产一区二区三区在线臀色熟女| 一夜夜www| 国产成人aa在线观看| 成熟少妇高潮喷水视频| 看片在线看免费视频| 精品一区二区三区视频在线观看免费| 18禁黄网站禁片免费观看直播| 亚洲最大成人中文| 国产爱豆传媒在线观看| 国产成年人精品一区二区| 午夜亚洲福利在线播放| 精品欧美国产一区二区三| 久久精品国产99精品国产亚洲性色| 国产伦精品一区二区三区四那| 国产高清不卡午夜福利| 少妇被粗大猛烈的视频| 国产精品爽爽va在线观看网站| 亚洲成人久久爱视频| 观看免费一级毛片| 午夜日韩欧美国产| 欧美最新免费一区二区三区| 色在线成人网| 精品久久久久久久久av| 欧美zozozo另类| 麻豆精品久久久久久蜜桃| 国产精品一区二区免费欧美| 国产白丝娇喘喷水9色精品| 国产真实伦视频高清在线观看 | 91av网一区二区| 欧美一区二区国产精品久久精品| 午夜激情欧美在线| 日韩一区二区视频免费看| 三级男女做爰猛烈吃奶摸视频| 97人妻精品一区二区三区麻豆| 国产黄色小视频在线观看| 99热这里只有是精品在线观看| 看片在线看免费视频| 国产老妇女一区| 五月伊人婷婷丁香| 嫩草影院新地址| 狂野欧美白嫩少妇大欣赏| 精品一区二区三区av网在线观看| 黄色日韩在线| 日本五十路高清| 长腿黑丝高跟| 在现免费观看毛片| 九九爱精品视频在线观看| 亚洲性久久影院| 色综合色国产| 日韩一本色道免费dvd| 他把我摸到了高潮在线观看| 免费看美女性在线毛片视频| 在线观看美女被高潮喷水网站| 性色avwww在线观看| 久久精品国产亚洲网站| 中出人妻视频一区二区| 赤兔流量卡办理| 日本-黄色视频高清免费观看| 久久婷婷人人爽人人干人人爱| 午夜亚洲福利在线播放| 非洲黑人性xxxx精品又粗又长| 精品一区二区三区av网在线观看| 麻豆成人av在线观看| av天堂在线播放| 成人特级av手机在线观看| av女优亚洲男人天堂| 人妻丰满熟妇av一区二区三区| 国产亚洲精品久久久久久毛片| 国产午夜精品久久久久久一区二区三区 | 五月伊人婷婷丁香| 直男gayav资源| 一卡2卡三卡四卡精品乱码亚洲| 91在线观看av| 两个人的视频大全免费| 99热网站在线观看| 夜夜爽天天搞| 日本在线视频免费播放| 亚洲中文字幕日韩| 日韩精品有码人妻一区| 免费观看人在逋| 热99re8久久精品国产| 精品久久久久久久人妻蜜臀av| 又粗又爽又猛毛片免费看| 精品久久国产蜜桃| 午夜精品在线福利| 国产色爽女视频免费观看| 精品不卡国产一区二区三区| 男女下面进入的视频免费午夜| 亚洲性夜色夜夜综合| 少妇人妻精品综合一区二区 | 蜜桃亚洲精品一区二区三区| 午夜免费男女啪啪视频观看 | 日韩欧美国产在线观看| 国产探花极品一区二区| 国产真实伦视频高清在线观看 | 级片在线观看| 又紧又爽又黄一区二区| 日日撸夜夜添| 日韩欧美精品免费久久| 九九爱精品视频在线观看| 精品福利观看| www日本黄色视频网| 亚洲五月天丁香| 精品久久久久久成人av| 91在线观看av| 搡老岳熟女国产| 欧美zozozo另类| 91精品国产九色| 国语自产精品视频在线第100页| 两性午夜刺激爽爽歪歪视频在线观看| 日韩精品青青久久久久久| 久久久久久国产a免费观看| 在线免费十八禁| 在线播放无遮挡| 亚洲自拍偷在线| 午夜老司机福利剧场| 国产aⅴ精品一区二区三区波| 国产精品综合久久久久久久免费| 九色成人免费人妻av| 免费看日本二区| 色综合婷婷激情| 国内少妇人妻偷人精品xxx网站| 有码 亚洲区| 婷婷丁香在线五月| 国产精品一区二区三区四区免费观看 | 男人舔奶头视频| 俄罗斯特黄特色一大片| 久久久久久久久久久丰满 | 国产熟女欧美一区二区| 99热只有精品国产| 国产欧美日韩一区二区精品| 麻豆一二三区av精品| avwww免费| 欧美xxxx黑人xx丫x性爽| 国产aⅴ精品一区二区三区波| 精品一区二区三区视频在线观看免费| 免费看美女性在线毛片视频| 亚洲精品乱码久久久v下载方式| 黄色配什么色好看| 国产伦精品一区二区三区视频9| 国产人妻一区二区三区在| 18+在线观看网站| 3wmmmm亚洲av在线观看| 免费观看的影片在线观看| av在线亚洲专区| 国内揄拍国产精品人妻在线| 午夜免费激情av| 国产欧美日韩精品一区二区| 日韩欧美 国产精品| 欧美激情在线99| 国产av一区在线观看免费| 久久热精品热| 毛片一级片免费看久久久久 | 在线观看舔阴道视频| 丰满的人妻完整版| 国产精品一区www在线观看 | 一区二区三区高清视频在线| 俄罗斯特黄特色一大片| 免费黄网站久久成人精品| 不卡一级毛片| 久久久久久久久大av| 欧美成人一区二区免费高清观看| 可以在线观看毛片的网站| 亚洲成人精品中文字幕电影| 深爱激情五月婷婷| 无人区码免费观看不卡| 老司机深夜福利视频在线观看| avwww免费| 国产成人影院久久av| 波多野结衣巨乳人妻| 无遮挡黄片免费观看| 亚洲黑人精品在线| 十八禁国产超污无遮挡网站| 国产午夜福利久久久久久| 久久久精品欧美日韩精品| 女的被弄到高潮叫床怎么办 | 全区人妻精品视频| 99久久无色码亚洲精品果冻| 亚洲国产精品合色在线| av在线天堂中文字幕| 成人一区二区视频在线观看| 国产精品,欧美在线| 亚洲美女搞黄在线观看 | 成人毛片a级毛片在线播放| 欧美成人a在线观看| 小说图片视频综合网站| 欧美性感艳星| 日日夜夜操网爽| 久久精品久久久久久噜噜老黄 | 成人av一区二区三区在线看| 欧美黑人巨大hd| 欧美高清性xxxxhd video| 日韩欧美 国产精品| 色播亚洲综合网| 中文资源天堂在线| 国产精品一及| 97超级碰碰碰精品色视频在线观看| 国产老妇女一区| 听说在线观看完整版免费高清| 亚洲天堂国产精品一区在线| 2021天堂中文幕一二区在线观| 久久国内精品自在自线图片| 不卡视频在线观看欧美| 一个人免费在线观看电影| 亚洲三级黄色毛片| 国产伦精品一区二区三区视频9| 久久久久性生活片| 国产一区二区三区视频了| 超碰av人人做人人爽久久| 国产色爽女视频免费观看| 成人三级黄色视频| 禁无遮挡网站| 亚洲最大成人中文| 国产精品国产三级国产av玫瑰| 午夜激情福利司机影院| 日韩中文字幕欧美一区二区| 欧美性感艳星| 天堂网av新在线| 久久精品夜夜夜夜夜久久蜜豆| 日本撒尿小便嘘嘘汇集6| 亚洲经典国产精华液单| 91久久精品国产一区二区三区| 国产又黄又爽又无遮挡在线| 此物有八面人人有两片| 亚洲av第一区精品v没综合| 欧美一级a爱片免费观看看| 久久精品人妻少妇| 性色avwww在线观看| 久久久久国产精品人妻aⅴ院| 午夜亚洲福利在线播放| 国产av麻豆久久久久久久| 日韩欧美一区二区三区在线观看| 最新在线观看一区二区三区| 99久久久亚洲精品蜜臀av| 亚洲av免费高清在线观看| 久久精品91蜜桃| 一区二区三区四区激情视频 | 91狼人影院| 日韩欧美三级三区| 亚洲一区高清亚洲精品| 精品一区二区三区人妻视频| 性色avwww在线观看| 特级一级黄色大片| 日日干狠狠操夜夜爽| 国产精品电影一区二区三区| 国产蜜桃级精品一区二区三区| 国产亚洲欧美98| 色哟哟哟哟哟哟| 日本一二三区视频观看| 一个人看视频在线观看www免费| 88av欧美| 亚洲国产精品久久男人天堂| av在线观看视频网站免费| 久久九九热精品免费| av福利片在线观看| 免费看美女性在线毛片视频| 中文字幕av在线有码专区| 国产一区二区三区视频了| 色播亚洲综合网| 91在线观看av| 亚洲av成人av| 色尼玛亚洲综合影院| 日韩精品青青久久久久久|